Brief: Sensei Biotherapeutics Announces Ind Clearance By U.S. FDA Enabling Phase 1 Initiation For Sns-101, A Conditionally Active Vista-Blocking Antibody
20/04/2023 12:32
April 20 (Reuters) - Sensei Biotherapeutics Inc
SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES IND CLEARANCE BY U.S. FDA
ENABLING PHASE 1 INITIATION FOR SNS-101, A CONDITIONALLY ACTIVE
VISTA-BLOCKING ANTIBODY
* SENSEI BIOTHERAPEUTICS INC - SENSEI EXPECTS TO DOSE FIRST
PATIENT IN MID-2023 FOR SNS-101
Source text for Eikon: ID:nGNX69N5MV
Further company coverage: SNSE.O
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)